<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04298034</url>
  </required_header>
  <id_info>
    <org_study_id>PRO36760</org_study_id>
    <nct_id>NCT04298034</nct_id>
  </id_info>
  <brief_title>Preeclamptic Postpartum Antihypertensive Treatment</brief_title>
  <acronym>P-PAT</acronym>
  <official_title>Randomized Controlled Trial for Postpartum Antihypertensive Treatment of Women With Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to compare whether antihypertensive treatment in the postpartum
      period decreases postpartum hypertension and its associated maternal morbidity, including
      risk of readmission and healthcare utilization in comparison with no treatment. Women with
      preeclampsia diagnosed during the antepartum, intrapartum or postpartum period will be
      randomized to either initiate antihypertensive treatment or standard of care. We hypothesize
      that postpartum antihypertensive treatment of patients with preeclampsia will decrease risk
      of hospital readmission, healthcare utilization and the number of severe range blood
      pressures at postpartum follow-up visits.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, controlled trial of 300 women with a diagnosis of preeclampsia at
      any point in their current pregnancy or immediately postpartum. Immediately postpartum is
      defined as preeclampsia diagnosed after delivery but prior to discharge from the hospital.
      The diagnosis of preeclampsia will be made using standardized definitions by the American
      College of Obstetrics and Gynecology. Preeclampsia is diagnosed with new-onset hypertension
      of blood pressure of greater than or equal to 140 systolic blood pressure or greater than or
      equal to 90 diastolic blood pressure recorded twice at least four hours apart AND
      proteinuria, defined as 300mg of protein in a 24hour urine collection or a protein/creatinine
      ratio of 0.3. If the above blood pressure criteria are met and there is not proteinuria,
      preeclampsia can still be diagnosed if there is thrombocytopenia with platelet count of less
      than 100,000, renal insufficiency with creatinine of greater than 1.1 or twice the patient's
      individual baseline, impaired liver function with AST or ALT twice normal or epigastric/right
      upper quadrant pain, pulmonary edema, new-onset headache unresponsive to medication, or
      visual disturbance. All of these findings should not be explained by an alternative
      diagnosis.

      Women will be consented and randomized at the time of their diagnosis, within 96 hours of
      their delivery. The patients randomized to the treatment group will have an antihypertensive
      medication prescribed to them. The specific medication will be either labetalol, nifedipine
      or hydralazine based on allergies and clinically appropriateness of the medication. The
      patient will be instructed on the dosing, timing, and possible adverse effects. All subject's
      blood pressures will be monitored per standard postpartum protocols. As per standard
      practice, all patients with preeclampsia will be asked to return at 7-10 days for a blood
      pressure check and then again at 6 weeks for a complete postpartum assessment.

      Consent of patients, review of blood pressures, data collection and storage, and statistical
      analysis will be performed at the Medical College of Wisconsin (MCW) through the Maternal
      Fetal medicine department. Women will be allowed to continue routine antenatal, intrapartum
      and postpartum care with their primary obstetrician. The research team will follow enrolled
      patients through the 6-week postpartum follow up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Statistician will be masked to which group the patient was randomized to.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital Readmission</measure>
    <time_frame>Within 6 weeks from delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Healthcare Utilization</measure>
    <time_frame>Within 6 weeks from delivery</time_frame>
    <description>hospital readmissions, increased number of postpartum visits or phone calls, emergency room or urgent care visits, consultation with primary care (internal medicine, family medicine), cardiology, or maternal-fetal-medicine specialists</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of severe range blood pressures at the 7-10 days postpartum visit</measure>
    <time_frame>7-10 days postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of severe range blood pressures at the 6 week postpartum visit</measure>
    <time_frame>Approximately 6 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compare mean systolic and mean diastolic blood pressure values at 7-10 days postpartum and at 6weeks postpartum</measure>
    <time_frame>6 weeks pospartum</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Preeclampsia</condition>
  <condition>Hypertension in Pregnancy</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients randomized to the treatment group will have an antihypertensive medication prescribed to them. The specific medication will be either labetalol or nifedipine based on allergies and clinically appropriateness of the medication. The patient will be instructed on the dosing, timing, and possible adverse effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No-treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Labetalol, Nifedipine</intervention_name>
    <description>Antihypertensive treatment that is safe and well studied in peripartum women.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Procardia</other_name>
    <other_name>Trandate, Normodyne</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18 years old

          -  Immediately postpartum (delivered in previous 96 hours)

          -  Diagnosed with preeclampsia during pregnancy, labor or immediately postpartum

          -  &gt;50% of blood pressures in the postpartum period were elevated (systolic 140 or higher
             OR diastolic 90 or higher)

        Exclusion Criteria:

          -  Chronic hypertension with superimposed preeclampsia

          -  Diagnosis of preeclampsia after discharge from delivery hospitalization

          -  Persistent severe range blood pressures after delivery requiring initiation of
             antihypertensive regimen by the care team

          -  &gt;50% of blood pressures in the postpartum period were normal (systolic less than 140
             AND diastolic less than 90)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mary Christine Livergood, MD</last_name>
    <phone>414-805-6624</phone>
    <email>mlivergood@mcw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Palatnik, MD</last_name>
    <phone>414-805-6624</phone>
    <email>apalatnik@mcw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical College of Wisconsin-Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Christine Livergood</last_name>
      <phone>314-346-3036</phone>
      <phone_ext>3143463036</phone_ext>
      <email>mlivergood@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anna Palatnik</last_name>
      <phone>414-805-6622</phone>
      <email>apalatnik@mcw.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sibai BM. Hypertensive disorders of pregnancy: the United States perspective. Curr Opin Obstet Gynecol. 2008 Apr;20(2):102-6. doi: 10.1097/GCO.0b013e3282f73380. Review.</citation>
    <PMID>18388806</PMID>
  </reference>
  <reference>
    <citation>Mogos MF, Salemi JL, Spooner KK, McFarlin BL, Salihu HH. Hypertensive disorders of pregnancy and postpartum readmission in the United States: national surveillance of the revolving door. J Hypertens. 2018 Mar;36(3):608-618. doi: 10.1097/HJH.0000000000001594.</citation>
    <PMID>29045342</PMID>
  </reference>
  <reference>
    <citation>Tan LK, de Swiet M. The management of postpartum hypertension. BJOG. 2002 Jul;109(7):733-6.</citation>
    <PMID>12135206</PMID>
  </reference>
  <reference>
    <citation>Ade-Conde JA, Alabi O, Higgins S, Visvalingam G. Maternal post natal hospital readmission-trends and association with mode of delivery. Ir Med J. 2011 Jan;104(1):17-20.</citation>
    <PMID>21387880</PMID>
  </reference>
  <reference>
    <citation>Clapp MA, Little SE, Zheng J, Robinson JN. A multi-state analysis of postpartum readmissions in the United States. Am J Obstet Gynecol. 2016 Jul;215(1):113.e1-113.e10. doi: 10.1016/j.ajog.2016.01.174.</citation>
    <PMID>27829570</PMID>
  </reference>
  <reference>
    <citation>Ferrazzani S, De Carolis S, Pomini F, Testa AC, Mastromarino C, Caruso A. The duration of hypertension in the puerperium of preeclamptic women: relationship with renal impairment and week of delivery. Am J Obstet Gynecol. 1994 Aug;171(2):506-12.</citation>
    <PMID>8059832</PMID>
  </reference>
  <reference>
    <citation>Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS, Shackelford KA, Steiner C, Heuton KR, Gonzalez-Medina D, Barber R, Huynh C, Dicker D, Templin T, Wolock TM, Ozgoren AA, Abd-Allah F, Abera SF, Abubakar I, Achoki T, Adelekan A, Ademi Z, Adou AK, Adsuar JC, Agardh EE, Akena D, Alasfoor D, Alemu ZA, Alfonso-Cristancho R, Alhabib S, Ali R, Al Kahbouri MJ, Alla F, Allen PJ, AlMazroa MA, Alsharif U, Alvarez E, Alvis-Guzmán N, Amankwaa AA, Amare AT, Amini H, Ammar W, Antonio CA, Anwari P, Arnlöv J, Arsenijevic VS, Artaman A, Asad MM, Asghar RJ, Assadi R, Atkins LS, Badawi A, Balakrishnan K, Basu A, Basu S, Beardsley J, Bedi N, Bekele T, Bell ML, Bernabe E, Beyene TJ, Bhutta Z, Bin Abdulhak A, Blore JD, Basara BB, Bose D, Breitborde N, Cárdenas R, Castañeda-Orjuela CA, Castro RE, Catalá-López F, Cavlin A, Chang JC, Che X, Christophi CA, Chugh SS, Cirillo M, Colquhoun SM, Cooper LT, Cooper C, da Costa Leite I, Dandona L, Dandona R, Davis A, Dayama A, Degenhardt L, De Leo D, del Pozo-Cruz B, Deribe K, Dessalegn M, deVeber GA, Dharmaratne SD, Dilmen U, Ding EL, Dorrington RE, Driscoll TR, Ermakov SP, Esteghamati A, Faraon EJ, Farzadfar F, Felicio MM, Fereshtehnejad SM, de Lima GM, Forouzanfar MH, França EB, Gaffikin L, Gambashidze K, Gankpé FG, Garcia AC, Geleijnse JM, Gibney KB, Giroud M, Glaser EL, Goginashvili K, Gona P, González-Castell D, Goto A, Gouda HN, Gugnani HC, Gupta R, Gupta R, Hafezi-Nejad N, Hamadeh RR, Hammami M, Hankey GJ, Harb HL, Havmoeller R, Hay SI, Pi IB, Hoek HW, Hosgood HD, Hoy DG, Husseini A, Idrisov BT, Innos K, Inoue M, Jacobsen KH, Jahangir E, Jee SH, Jensen PN, Jha V, Jiang G, Jonas JB, Juel K, Kabagambe EK, Kan H, Karam NE, Karch A, Karema CK, Kaul A, Kawakami N, Kazanjan K, Kazi DS, Kemp AH, Kengne AP, Kereselidze M, Khader YS, Khalifa SE, Khan EA, Khang YH, Knibbs L, Kokubo Y, Kosen S, Defo BK, Kulkarni C, Kulkarni VS, Kumar GA, Kumar K, Kumar RB, Kwan G, Lai T, Lalloo R, Lam H, Lansingh VC, Larsson A, Lee JT, Leigh J, Leinsalu M, Leung R, Li X, Li Y, Li Y, Liang J, Liang X, Lim SS, Lin HH, Lipshultz SE, Liu S, Liu Y, Lloyd BK, London SJ, Lotufo PA, Ma J, Ma S, Machado VM, Mainoo NK, Majdan M, Mapoma CC, Marcenes W, Marzan MB, Mason-Jones AJ, Mehndiratta MM, Mejia-Rodriguez F, Memish ZA, Mendoza W, Miller TR, Mills EJ, Mokdad AH, Mola GL, Monasta L, de la Cruz Monis J, Hernandez JC, Moore AR, Moradi-Lakeh M, Mori R, Mueller UO, Mukaigawara M, Naheed A, Naidoo KS, Nand D, Nangia V, Nash D, Nejjari C, Nelson RG, Neupane SP, Newton CR, Ng M, Nieuwenhuijsen MJ, Nisar MI, Nolte S, Norheim OF, Nyakarahuka L, Oh IH, Ohkubo T, Olusanya BO, Omer SB, Opio JN, Orisakwe OE, Pandian JD, Papachristou C, Park JH, Caicedo AJ, Patten SB, Paul VK, Pavlin BI, Pearce N, Pereira DM, Pesudovs K, Petzold M, Poenaru D, Polanczyk GV, Polinder S, Pope D, Pourmalek F, Qato D, Quistberg DA, Rafay A, Rahimi K, Rahimi-Movaghar V, ur Rahman S, Raju M, Rana SM, Refaat A, Ronfani L, Roy N, Pimienta TG, Sahraian MA, Salomon JA, Sampson U, Santos IS, Sawhney M, Sayinzoga F, Schneider IJ, Schumacher A, Schwebel DC, Seedat S, Sepanlou SG, Servan-Mori EE, Shakh-Nazarova M, Sheikhbahaei S, Shibuya K, Shin HH, Shiue I, Sigfusdottir ID, Silberberg DH, Silva AP, Singh JA, Skirbekk V, Sliwa K, Soshnikov SS, Sposato LA, Sreeramareddy CT, Stroumpoulis K, Sturua L, Sykes BL, Tabb KM, Talongwa RT, Tan F, Teixeira CM, Tenkorang EY, Terkawi AS, Thorne-Lyman AL, Tirschwell DL, Towbin JA, Tran BX, Tsilimbaris M, Uchendu US, Ukwaja KN, Undurraga EA, Uzun SB, Vallely AJ, van Gool CH, Vasankari TJ, Vavilala MS, Venketasubramanian N, Villalpando S, Violante FS, Vlassov VV, Vos T, Waller S, Wang H, Wang L, Wang X, Wang Y, Weichenthal S, Weiderpass E, Weintraub RG, Westerman R, Wilkinson JD, Woldeyohannes SM, Wong JQ, Wordofa MA, Xu G, Yang YC, Yano Y, Yentur GK, Yip P, Yonemoto N, Yoon SJ, Younis MZ, Yu C, Jin KY, El Sayed Zaki M, Zhao Y, Zheng Y, Zhou M, Zhu J, Zou XN, Lopez AD, Naghavi M, Murray CJ, Lozano R. Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014 Sep 13;384(9947):980-1004. doi: 10.1016/S0140-6736(14)60696-6. Epub 2014 May 2. Erratum in: Lancet. 2014 Sep 13;384(9947):956.</citation>
    <PMID>24797575</PMID>
  </reference>
  <reference>
    <citation>ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2019 Jan;133(1):e1-e25. doi: 10.1097/AOG.0000000000003018.</citation>
    <PMID>30575675</PMID>
  </reference>
  <reference>
    <citation>Levine LD, Nkonde-Price C, Limaye M, Srinivas SK. Factors associated with postpartum follow-up and persistent hypertension among women with severe preeclampsia. J Perinatol. 2016 Dec;36(12):1079-1082. doi: 10.1038/jp.2016.137. Epub 2016 Sep 1.</citation>
    <PMID>27583396</PMID>
  </reference>
  <reference>
    <citation>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstet Gynecol. 2019 Jan;133(1):e26-e50. doi: 10.1097/AOG.0000000000003020.</citation>
    <PMID>30575676</PMID>
  </reference>
  <reference>
    <citation>Boffa RJ, Constanti M, Floyd CN, Wierzbicki AS; Guideline Committee. Hypertension in adults: summary of updated NICE guidance. BMJ. 2019 Oct 21;367:l5310. doi: 10.1136/bmj.l5310.</citation>
    <PMID>31636059</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Anna Palatnik, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Hypertension, Pregnancy-Induced</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Labetalol</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

